Effect of Artemisia vulgaris Extract on Granzyme Expression and Tumor Mass Diameter (Study of Adriamycin Cyclophosphamide Chemotherapy in Adenocarcinoma Mammae C3H Mice Model)

<p>Breast cancer incident continues to increase globally. The surgical management can be combined with other therapeutic modalities, including chemotherapy, radiation, and immunotherapy, such as Artemisia vulgaris (AV). This study aimed to determine the effect of AV extract on Granzyme expression and tumor mass diameter growth of C3H mice with adenocarcinoma mammae. Twenty-four female C3H mice were randomly divided into groups of K (control), P1 (AC chemotherapy), P2 (AV extract), and P3 (combination). Adenocarcinoma mammae were inoculated from donor mice. Two cycles of chemotherapy by Adriamycin 0.18 mg and Cyclophosphamide 1.8 mg were given intravenously, while Artemisia vulgaris 13 mg (0.2 ml) was given orally once per day. Granzyme expression was assessed using immunohistochemical staining, while tumor mass diameter growth was measured using tumor calipers. There was a significant negative correlation between and tumor mass diameter growth (p=0,001 and r=-0,911). Artemisia vulgaris increases the apoptotic effects of Adriamycin-Cyclophosphamide chemotherapy by increasing Granzyme expression and decreasing tumor mass diameter growth in adenocarcinoma mammae C3H mice.</p>

Expression Profiles and Potential Functions of Long Non-Coding RNAs in the Heart of Mice With Coxsackie B3 Virus-Induced Myocarditis

AimsLong non-coding RNAs (lncRNAs) are critical regulators of viral infection and inflammatory responses. However, the roles of lncRNAs in acute myocarditis (AM), especially fulminant myocarditis (FM), remain unclear.MethodsFM and non-fulminant myocarditis (NFM) were induced by coxsackie B3 virus (CVB3) in different mouse strains. Then, the expression profiles of the lncRNAs in the heart tissues were detected by sequencing. Finally, the patterns were analyzed by Pearson/Spearman rank correlation, Kyoto Encyclopedia of Genes and Genomes, and Cytoscape 3.7.ResultsFirst, 1,216, 983, 1,606, and 2,459 differentially expressed lncRNAs were identified in CVB3-treated A/J, C57BL/6, BALB/c, and C3H mice with myocarditis, respectively. Among them, 88 lncRNAs were commonly dysregulated in all four models. Quantitative real-time polymerase chain reaction analyses further confirmed that four out of the top six commonly dysregulated lncRNAs were upregulated in all four models. Moreover, the levels of ENSMUST00000188819, ENSMUST00000199139, and ENSMUST00000222401 were significantly elevated in the heart and spleen and correlated with the severity of cardiac inflammatory infiltration. Meanwhile, 923 FM-specific dysregulated lncRNAs were detected, among which the levels of MSTRG.26098.49, MSTRG.31307.11, MSTRG.31357.2, and MSTRG.32881.28 were highly correlated with LVEF.ConclusionExpression of lncRNAs is significantly dysregulated in acute myocarditis, which may play different roles in the progression of AM.

Monitoring vascular changes induced by photodynamic therapy using contrast-enhanced micro-computed tomography

The aim of this study is to determine if contrast-enhanced micro-computed tomography can be used to non-invasively image the response of vasculature in tumours that have been treated with photodynamic theraphy (PDT). The subjects used were C3H mice with RIF-1 tumour implanted subcutaneously and allowed to grow for 3 weeks prior to treatment. The subjects in this study were divided into PDT treated groups (150 J/cm², 50 J/cm²) and control groups (150 J/cm² light-only, untreated). The contast-enhanced micro-computed tomography imaging procedure consisted of eight-second scans taking place before treatment and up to 24 hours after treatment. The treatment response was evaluated through the ration of blood-to-tumour volume. Significant changes were detected at 8 and 24 hours in the 150 J/cm² PDT group (p< 0.01). Immunohistochemical staining confirmed the effects of each treatment in comparison to the control groups.

Monitoring vascular changes induced by photodynamic therapy using contrast-enhanced micro-computed tomography

The aim of this study is to determine if contrast-enhanced micro-computed tomography can be used to non-invasively image the response of vasculature in tumours that have been treated with photodynamic theraphy (PDT). The subjects used were C3H mice with RIF-1 tumour implanted subcutaneously and allowed to grow for 3 weeks prior to treatment. The subjects in this study were divided into PDT treated groups (150 J/cm², 50 J/cm²) and control groups (150 J/cm² light-only, untreated). The contast-enhanced micro-computed tomography imaging procedure consisted of eight-second scans taking place before treatment and up to 24 hours after treatment. The treatment response was evaluated through the ration of blood-to-tumour volume. Significant changes were detected at 8 and 24 hours in the 150 J/cm² PDT group (p< 0.01). Immunohistochemical staining confirmed the effects of each treatment in comparison to the control groups.

The Effectivity of Supplementation Artemisia vulgaris for Adenocarcinoma Mammae Chemotherapy to Reduce CD 34 and Tumor Massa Diameter (Study in C3H Mice Given Adriamycin - Cyclophosphamide Chemotherapy)

Introduction: Breast cancer is still a major health problem in the world. In the case of breast cancer, surgery is the main treatment option besides chemotherapy, radiation, and immunotherapy such as Artemisia vulgaris (AV). AV is cytotoxic selectively acts as a supplement to breast adenocarcinoma chemotherapy given the Adriamycin-Cyclophosphamide regimen, to improve chemotherapy response.The study was aimed to proving AV extract enhances the chemotherapy response in C3H mice with adenocarcinoma mammae given Adriamycin-Cyclophosphamide Chemotherapy. Method: This study used Post test only control group design on 24 females C3H mice that were randomly selected and divided into four groups: group K (control), P1 (chemotherapy), P2 (extract), and P3 (combination). Adenocarcinoma mammae comes from the inoculation of donor mice. Chemotherapy of Adriamycin 60 mg / m 2 and Cyclophosphamide 600 mg / m 2 were given in two cycles. AV 13 mg (0.2 ml) was given once daily orally. CD34 were evaluated by imunohistochemical staining and tumor mass diameter were counted by calipers. Result: The microvascular density CD34 and tumor mass diameter were obtained in groups of K, P1, P2, P3 respectively 60.76 ± 1.5; 39.70 ± 2.00; 57.10 ± 1.29; 35.26 ± 2.06 and 12.52 ± 1.49; 6.20 + 1.04; 9,94 + 1.21; 3.94 + 0.76. Statistical analysis showed significant differences in CD34 between groups K vs P1, P2, P3 (p = 0.001, p = 0.014, p = 0.001), P1 vs P2 and P3 (p = 0.001, p = 0.033) and P2 (P = 0.001). Tumor mass diameter between groups K vs P1, P2, P3 (p=0.001; p=0.014; p=0,001), P1 with P2 (p= 0.001) P1 with P3 (p = 0.033) and P2 with P3 (p = 0.001). Correlation analysis between CD34 with tumor mass diameter was found to have significant correlation (p = 0.001 and r = 0.932). Conclusion: Artemisia vulgaris is a potential to reduce angiogenesis in terms of decreasing the microvascular density CD34 and tumor mass diameter of adenocarcinoma mammae of C3H mice treated with Adriamycin-Cyclophosphamide chemotherapy and can improve the effectivity.

The Effectivity of Supplementation Artemisia vulgaris for Adenocarcinoma Mammae Chemotherapy to Reduce CD 34 and Tumor Massa Diameter (Study in C3H Mice Given Adriamycin - Cyclophosphamide Chemotherapy)

Introduction: Breast cancer is still a major health problem in the world. In the case of breast cancer, surgery is the main treatment option besides chemotherapy, radiation, and immunotherapy such as Artemisia vulgaris (AV). AV is cytotoxic selectively acts as a supplement to breast adenocarcinoma chemotherapy given the Adriamycin-Cyclophosphamide regimen, to improve chemotherapy response.The study was aimed to proving AV extract enhances the chemotherapy response in C3H mice with adenocarcinoma mammae given Adriamycin-Cyclophosphamide Chemotherapy. Method: This study used Post test only control group design on 24 females C3H mice that were randomly selected and divided into four groups: group K (control), P1 (chemotherapy), P2 (extract), and P3 (combination). Adenocarcinoma mammae comes from the inoculation of donor mice. Chemotherapy of Adriamycin 60 mg / m 2 and Cyclophosphamide 600 mg / m 2 were given in two cycles. AV 13 mg (0.2 ml) was given once daily orally. CD34 were evaluated by imunohistochemical staining and tumor mass diameter were counted by calipers. Result: The microvascular density CD34 and tumor mass diameter were obtained in groups of K, P1, P2, P3 respectively 60.76 ± 1.5; 39.70 ± 2.00; 57.10 ± 1.29; 35.26 ± 2.06 and 12.52 ± 1.49; 6.20 + 1.04; 9,94 + 1.21; 3.94 + 0.76. Statistical analysis showed significant differences in CD34 between groups K vs P1, P2, P3 (p = 0.001, p = 0.014, p = 0.001), P1 vs P2 and P3 (p = 0.001, p = 0.033) and P2 (P = 0.001). Tumor mass diameter between groups K vs P1, P2, P3 (p=0.001; p=0.014; p=0,001), P1 with P2 (p= 0.001) P1 with P3 (p = 0.033) and P2 with P3 (p = 0.001). Correlation analysis between CD34 with tumor mass diameter was found to have significant correlation (p = 0.001 and r = 0.932). Conclusion: Artemisia vulgaris is a potential to reduce angiogenesis in terms of decreasing the microvascular density CD34 and tumor mass diameter of adenocarcinoma mammae of C3H mice treated with Adriamycin-Cyclophosphamide chemotherapy and can improve the effectivity.

Effect of Artemisia vulgaris Extract on P53 Expression and Caspase-8 Expression (Study on Adenocarcinoma Mammae C3H Mice Given Adriamycin- Cyclophosphamide Chemotherapy Regimen)

Background: The incidence of breast cancer worldwide is still high. Surgery remains the top choice with other modalities of chemotherapy. radiation. and immunotherapy such as Artemisia vulgaris (AV). Purpose : The study was aimed to demonstrate that administration of AV extract increased the levels of p53 and Caspase-8 in adenocarcinoma mammae. Methods: This study used "Post test only control group design" on 24 females C3H mice that were randomly selected and divided into four groups : group K (control). P1 (chemotherapy). P2 (extract). and P3 (combination). Adenocarcinoma mammae comes from the inoculation of donor mice. Chemotherapy of Adriamycin 0.18 mg and Cyclophosphamide 1.8 mg were given in 2 cycles. AV 13 mg (0.2 ml) was given once daily orally. P53 and Caspase-8 levels were evaluated by imunohistochemical staining. Results: Mean of p53 and Caspase-8 levels were found in groups K. P1. P2. P3 were 22.06+1.73. 37.16+1.20. 24.60+1.08. 39.78+1.19 dan 17.16+1.28. 26.20+1.11. 24.60+1.08. 39.78+1.19. The statistical analysis showed that there were significant differences in the levels of p53 between groups of K vs P1. P3 (p=0.001). K vs P2 (p=0.048). P1 vs P2 (p=0.001). P1 vs P3 (p=0.039). P2 vs P3 (p=0.001). and in Caspase-8 between groups of K vs P1. P3 (p=0.001). K vs P2 (p=0.048). P1 vs P2 (p=0.001). P1 vs P3 (p=0.039). P2 vs P3 (p=0.001). Correlation analysis between p53 and Caspase-8 showed significant correlation (p=0.047 dan r=0.883). Conclusion: Artemisia vulgaris can improve the effectivity of Adriamycin- Cyclophosphamide chemotherapy on C3H mice with adenocarcinoma mammae in terms of elevated levels of P53 and Caspase-8.

Effectiveness of Artemisia Vulgaris as Supplementation Against Chemotherapy of Mammae Adenocarcinoma to Reduce Expression of NF-κB and CD 34 (Study in C3H Mice Given Chemotherapy Adriamycin - Cyclophosphamide)

Intoduction: Breast cancer is a significant healthcare problem worldwide. Surgery remains the treatment of choice combined with other modalities such as chemotherapy, radiation, and immunotherapy such as Artemisia vulgaris (AV). Selective cytotoxicity of AV is intended as a supplementation to Adriamycin-Cyclophosphamide, improving the response rate of chemotherapy in adenocarcinoma mammae. Method: This study used a "Post-test only control group design" on 24 females C3H mice that were randomly selected and divided into four groups: group K (control), P1 (chemotherapy), P2 (extract), and P3 (combination). Adenocarcinoma mammae come from the inoculation of donor mice. Chemotherapy of Adriamycin 60 mg / m 2 and Cyclophosphamide 600 mg / m 2 were given in two cycles. AV 13 mg (0.2 ml) was given once daily orally. NF-κB expression and CD34were evaluated using imunohistochemical staining. Result: The expression of NF-κB and microvascular density of CD 34 were obtained in groups of K, P1, P2, P3 Statistical analysis showed significant decrease in the expression of NF-κB between groups K and P1, P2, P3. Correlation analysis between NF-κB expression with CD 34 was found to have significant correlation (p = 0,039 and r = 0,897). Conclusion:Artemisia vulgaris can reduce angiogenesis by decreasing NF-κB expression and the microvascular density CD34 of adenocarcinoma mammae of C3H mice treated with Adriamycin-Cyclophosphamide chemotherapy and can improve the effectivity.